Antiplatelet effects of Spatholobus suberectus via inhibition of the glycoprotein IIb/IIIa receptor
作者 Lee, Beom-Joon; Jo, In-Young; Bu, Youngmin; Park, Jae-Woo; Maeng, Sungho; Kang, Hee; Jang, Woochang; Hwang, Deok-Sang; Lee, Wookyoung; Min, Kyoungyoon; Kim, Jong-In; Yoo, Hye Hyun; Lew, Jae-Hwan
期刊 JOURNAL OF ETHNOPHARMACOLOGY , NOV 4 2015,:174
摘要
Ethnopharmacological relevance: The vine stem of Spatholobus suberectus is a widely used blood-activating and stasis-dispelling medicine for the treatment of diseases related to blood stasis syndrome in traditional medicine in Korea, Japan, and China.Aim of the study: To demonstrate the clinical effects of Spatholobus suberectus against blood stasis syndromes using in vitro and in vivo platelet aggregation studies and to investigate its exact mechanisms. Materials and methods: We extracted vine stems of Spatholobus suberectus, using 95% EtOH (SSE) and investigated its antiplatelet activity on platelet aggregation induced by collagen and ADP in human platelet-rich plasma (PRP). For the mechanism study, a glycoprotein IIb/IIIa (GP IIb/IIIa) assay using flow cytometric analysis and a thromboxane A(2) (TXA(2)) assay were performed. In addition, we investigated the effects of SSE in a thromboembolic mouse model.Results: SSE significantly inhibited ADP- and collagen-induced platelet aggregation in human PRP concentration-dependently without affecting plasma clotting time. It also significantly inhibited fibrinogen binding to the GP IIb/IIIa receptor and partly inhibited the formation of TXA(2). In the in vivo study, oral administration of SSE dose-dependently suppressed the death of thromboembolism model mice induced by intravenous injection of collagen plus epinephrine.Conclusions: SSE showed antiplatelet activity without anticoagulant effects mainly through the inhibition of fibrinogen binding to the GP IIb/IIIa receptor. Our current results support the clinical usage of SSE in the East Asian region treating atherothrombotic diseases and may represent a new natural source to develop antiplatelet agents. (C) 2011 Elsevier Ireland Ltd. All rights reserved.